Skip to main content

Table 3 Characteristics of HBsAg-positive patients with hepatic dysfunction and without hepatic dysfunction during chemotherapy

From: Clinical and prognostic analysis of hepatitis B virus infection in diffuse large B-cell lymphoma

  Patients with hepatic dysfunction (No = 40) (49.4%) Patients without hepatic dysfunction (No = 41) (50.6%) p-value
Sex    0.22
Male 23(57.5) 18(43.9)  
Female 17(42.5) 23(56.1)  
Age (years)    0.096
≤ 60 28(70) 35(85.4)  
> 60 12(30) 6(14.6)  
Staging    0.088
I/II 13(32.5) 21(51.2)  
III/IV 27(67.5) 20(48.8)  
B symptom    0.43
Positive 15(37.5) 12(29.3)  
Negative 25(62.5) 29(70.7)  
PS    0.41
0,1 38(95) 37(90.2)  
2,3,4 2(5) 4(9.8)  
LDH    0.75
≤ Normal value 22(55) 24(58.5)  
> Normal value 18(45) 17(41.5)  
Extranodal sites    0.42
0–1 34(85) 32(78)  
> 1 6(15) 9(22)  
Liver involvement    0.63
Yes 7(17.5) 5(12.2)  
No 33(82.5) 36(87.8)  
Spleen involvement    0.50
Yes 12(30) 11(26.8)  
No 28(70) 30(73.2)  
HBV status prior to CT    0.38
HBsAg(+), HBeAg(+), Anti-HBc(+) 11(27.5) 15(36.6)  
HBsAg(+), Anti-HBe(+), Anti-HBc(+) 29(72.5) 26(63.4)  
Liver dysfunction prior to CT    0.38
Yes 10(25) 7(17.1)  
No 30(75) 34(82.9)  
Radiation    0.037
Yes 8(20) 17(41.5)  
No 32(80) 24(58.5)  
Chemotherapy    0.90
No. Range 2–20 1–13  
Median 6 6  
Response to front-line chemotherapy    0.26
CR 18(45) 25(61)  
PR 19(47.5) 12(29.3)  
SD 1(2.5) 3(7.3)  
PD 2(5) 1(2.4)